Core Viewpoint - The company, Iminconco-B (01541), has submitted an application for the III phase clinical trial of IMM0306, a dual-targeting bispecific molecule targeting CD47 and CD20, marking it as the first of its kind to enter clinical stages globally [1] Group 1: Clinical Developments - The company has independently developed IMM0306, which targets both CD47 and CD20, and holds global intellectual property and commercialization rights for this molecule [1] - The company previously announced I phase data for IMM2510 at the 2025 World Lung Cancer Conference, reporting an overall response rate (ORR) of 35.3% and a progression-free survival (PFS) of 9.4 months, indicating excellent clinical data and safety [1] Group 2: Market Position and Valuation - The company is recognized as a global innovator in CD47 fusion proteins, with a rich pipeline and broad application prospects in oncology and autoimmune diseases [1] - Current market capitalization is approximately 5.7 billion HKD, suggesting that the company's value is significantly underestimated, prompting recommendations for active monitoring [1]